Replies to post #200779 on Biotech Values

[dewophile]

ENTA

That is impressive. GILD's data in DAA failures is impressive too.

HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS (View abstract)

https://events.easl.eu/EventProgramme/ILC2016.aspx

I think DAA failures should enable accelerated approval.